Low incidence of GvHD and rejection after pharmacological ex vivo modulation of bone marrow in 2-3 antigens mismatched BMT.
2-3 antigens mismatched BMT were performed on 32 children without a matched sibling donor. In the light of previous in vitro studies, which suggested a role of Vincristine and Methilprednisolone ex vivo treatment in modulating alloreactivity of T cells, bone marrow was treated with such a pharmacological cocktail before being infused. Acute GVHD 2 degrees to 4 degrees degree occurred in 46% of cases, chronic GVHD in 28%, graft failure in 13%. There was no significant difference between 2- and 3-antigens mismatched BMT as far as GVHD and graft failure are concerned.
de Manzini
A
A
Department of Pediatrics, Trieste, Italy.
Andolina
M
M
Agosti
E
E
Giorgi
R
R
Locatelli
F
F
Bonetti
L
L
Miniero
R
R
Busca
A
A
Porta
F
F
Lanfranchi
A
A
D001853:Bone Marrow / Q000187:drug effects* / Q000276:immunology; D016026:Bone Marrow Transplantation / Q000276:immunology*; D002648:Child; D006084:Graft Rejection / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D006086:Graft vs Host Disease / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D006680:HLA Antigens / Q000276:immunology*; D006648:Histocompatibility / Q000276:immunology*; D006801:Humans; D015994:Incidence; D008775:Methylprednisolone / Q000494:pharmacology* / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D014750:Vincristine / Q000494:pharmacology* / Q000627:therapeutic use
D006680:HLA Antigens; D014750:Vincristine; D008775:Methylprednisolone